GlaxoSmithKline buys US partner in $3bn deal

GlaxoSmithKline boosted its pipeline of drugs today with a $3bn (€2.44bn) deal for its American partner on a potential blockbuster medicine.

GlaxoSmithKline buys US partner in $3bn deal

GlaxoSmithKline boosted its pipeline of drugs today with a $3bn (€2.44bn) deal for its American partner on a potential blockbuster medicine.

The proposed acquisition of Human Genome Sciences (HGS) means it has secured the full rights for Benlysta, the first new drug to be approved to treat immune system disease lupus in the US for more than 50 years.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited